Gts Securities LLC Mannkind Corp Call Options Transaction History

Gts Securities LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	SELL	$5.01 - $6.7 $284,568 - $380,560	-56,800 Reduced 46.29%	65,900 $413,000
Q2 2024 Aug 14, 2024	SELL	$4.05 - $5.43 $202,905 - $272,043	-50,100 Reduced 28.99%	122,700 $640,000
Q1 2024 May 15, 2024	BUY	$3.25 - $5.27 $475,475 - $771,000	146,300 Added 552.08%	172,800 $782,000
Q4 2023 Feb 14, 2024	SELL	$3.34 - $4.29 $217,100 - $278,850	-65,000 Reduced 71.04%	26,500 $96,000
Q3 2023 Nov 15, 2023	BUY	$3.91 - $5.45 $357,765 - $498,675	91,500 New	91,500 $377,000

245

148M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.53B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.